X0306 4 2017-02-13 1 0001590750 MIRAGEN THERAPEUTICS, INC. MGEN 0001005790 LEBOW BENNETT S 667 MADISON AVENUE, 14TH FLOOR NEW YORK NY 10065 1 0 1 0 Common Stock 2017-02-13 4 M 0 279067 5.39 A 280600 D Common Stock 148841 I By LeBow Alpha, LLLP Unsecured Demand Promissory Note 5.39 2017-02-13 4 A 0 1045000.00 0.00 A 2017-02-13 Common Stock 1045000.00 D Unsecured Demand Promissory Note 5.39 2017-02-13 4 M 0 1045000.00 0.00 D 2017-02-13 Common Stock 279067 0 D Immediately prior to the effective time of the Merger, that certain Unsecured Demand Promissory Note (the "Note"), dated March 6, 2015, as amended, issued by the issuer to the reporting person was converted into Common Stock. See footnote (4). On November 4, 2016, the issuer effected a one-for-15 reverse split of its Common Stock (the "Reverse Split"), and the number of securities and/or the conversion price reported reflect the Reverse Split. These shares are owned by LeBow Alpha, LLLP ("LeBow Alpha"). The reporting person is President of the general partner of LeBow Alpha and, as such, has the power to vote and dispose of the shares owned by LeBow Alpha. The reporting person disclaims beneficial ownership of those shares owned by LeBow Alpha except to the extent of his pecuniary interest therein. On October 31, 2016, the issuer and the reporting person agreed, subject to the approval of the issuer's stockholders which was given on February 10, 2017, to amend the Note to provide for automatic conversion of the unpaid principal balance and all accrued interest on the Note (the "Outstanding Balance"), plus a premium of 11% on the Outstanding Balance (the "Premium"), into Common Stock, immediately prior to the effective time of the Merger. The Merger closed on February 13, 2017. See "Remarks". At any time on or after June 30, 2015, the Note was payable upon demand of the reporting person. The number of shares of Common Stock into which the Note was made convertible is determined by dividing (i) the sum of the Outstanding Balance plus the Premium by (ii) the closing market price of the Common Stock on the Nasdaq Capital Market on October 31, 2016 of $5.39, as adjusted to reflect the Reverse Split (the "Conversion Price"). See footnote (6). The Outstanding Balance on February 13, 2017 was $1,355,365, consisting of an unpaid principal balance of $1,045,000 and accrued interest of $310,365. The Premium was $149,090.15. On February 13, 2017, a merger (the "Merger") was effected pursuant to that certain Agreement and Plan of Merger and Reorganization, dated October 31, 2016, by and among the issuer, Signal Merger Sub, Inc., a wholly owned subsidiary of the issuer ("Merger Sub"), and Miragen Therapeutics, Inc., a Delaware corporation ("Miragen"), whereby Merger Sub merged with and into Miragen, Merger Sub ceased to exist, and Miragen became a wholly-owned subsidiary of the issuer. At the closing of the Merger, the issuer changed its name and trading symbol from Signal Genetics, Inc. [SGNL] to Miragen Therapeutics, Inc. [MGEN]. /s/ Samuel D. Riccitelli, Attorney-in-Fact for Bennett S. Lebow 2017-02-13